메뉴 건너뛰기




Volumn 11, Issue 2, 2001, Pages 151-154

Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk

Author keywords

Abciximab; Coronary artery disease; GP IIb IIIa inhibitor; Percutaneous intervention; Platelet

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; WARFARIN;

EID: 0034917539     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011228817265     Document Type: Article
Times cited : (6)

References (8)
  • 3
    • 8544284052 scopus 로고    scopus 로고
    • Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of platelet IIb/IIIa inhibition for prevention of ischemic complication
    • (1997) JAMA , vol.278 , Issue.6 , pp. 479-484
    • Topol, E.J.1    Ferguson, J.J.2    Weisman, H.F.3
  • 6
    • 0034081573 scopus 로고    scopus 로고
    • Assessing the optimal level of platelet inhibition with GP IIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study
    • (2000) J Thromb Thrombolysis , vol.9 , Issue.3 , pp. 199-205
    • Steinhubl, S.R.1
  • 7
    • 0001378848 scopus 로고    scopus 로고
    • A prospective multicenter study to determine the optimal level of platelet inhibition with GP IIb/IIIa inhibitors in patients undergoing coronary intervention - The GOLD study
    • (2000) J Am Coll Cardiol , vol.35 , Issue.2 SUPPL. A
    • Steinhubl, S.1    Talley, D.2    Kereiakes, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.